Kejadian Ototoksik pada Anak dengan Keganasan yang Mendapat Kemoterapi Platinum Based
Ototoxicity Incidence in Children with Malignancy Who Received Platinum-Based Chemotherapy
DOI:
https://doi.org/10.36408/mhjcm.v9i2.690Keywords:
Ototoksik, Keganasan anak, KemoterapiAbstract
Latar belakang : Kejadian ototoksik pada anak dengan keganasan yang mendapatkan kemoterapi cisplatin 60–70%. Ototoksik pada anak menyebabkan gangguan perkembangan bahasa, kemampuan verbal dan komunikasi pada anak sehingga dapat menurunkan kualitas hidup. Tujuan penelitian ini adalah mengetahui kejadian ototoksik pada anak dengan keganasan yang mendapat kemoterapi platinum based.
Metode : Penelitian observasional analitik dengan design belah lintang pada anak dengan keganasan yang diberi kemoterapi platinum based periode Agustus – September 2020. Data diambil dari rekam medik pasien Klinik Onkologi Kasuari RSUP dr. Kariadi Semarang, ototoksik bila hasil OAE refer pada frekuensi ≥ 8KHz pada satu atau kedua telinga. Analisis data dengan uji Chi-Square.
Hasil : Didapatkan 38 sampel terdiri dari 22 laki-laki (57,89%) dan 16 perempuan (42,11%), dengan jenis kemoterapi cisplatin sebanyak 21 pasien (55,26%) dan jumlah pemberian kemoterapi ≥ 3 kali sebanyak 23 pasien (60,53%). Kejadian ototoksik lebih banyak pada jenis kelamin laki-laki, banyak terjadi pada pemberian kemoterapi cisplatin dan banyak terjadi pada pemberian ≥ 3 siklus. Jenis kelamin (p=0,248) dan Jenis kemoterapi (p=0,344) tidak berhubungan dengan kejadian ototoksik. Frekuensi siklus kemoterapi (p = 0,0005) berhubungan dengan kejadian ototoksik.
Simpulan : Kejadian ototoksik banyak pada anak laki laki, dengan keganasan yang mendapat kemoterapi cisplatin, banyak terjadi ototoksik pada pemberian ≥ 3 siklus, frekuensi siklus kemoterapi berhubungan dengan kejadian ototoksik
Downloads
References
Lee JW, Pussegoda K, Rassekh RS, et al. Clinical Practice Recommendations for the Management and Prevention of Cisplatin–Induced Hearing Loss Using Pharmacogenetic Markers. Therapeutic Drug Monitoring. 2016;38(4):423–431. doi:10.1097/FTD.0000000000000298
van As JW, van den Berg H, van Dalen EC. Platinum–induced hearing loss after treatment for childhood cancer. Cochrane D a t a b a s e o f S y s t e m a t i c R e v i e w s . 2 0 1 6 ; 2 0 1 6 ( 8 ) . doi:10.1002/14651858.CD010181.pub2
Kaul A, Malhotra T, Khan S. Role of otoacoustic emissions in the early detection and prevention of ototoxicity. Journal of Marine Medical Society. 2018;20(1):13. doi:10.4103/jmms.jmms_38_17
Susanah S. Chemotherapy Head and Neck Cancer in Paediatric Patients.; 2017.
BL A. Cancers and Benign Tumors : Epidemiology of Childhood and Adolescent Cancer. In: Nelson Textbook of Paediatrics. 20th ed. ; 2016:2422–2426.
Schwartz I, Hughes C, Brigger MT. Pediatric head and neck malignancies: Incidence and trends, 1973–2010. Otolaryngology
– Head and Neck Surgery (United States). 2015;152(6):1127-1132.
doi:10.1177/0194599815575714
Bass JK, Hua CH, Huang J, et al. Hearing loss in patients who received cranial radiation therapy for childhood cancer. Journal o f C l i n i c a l O n c o l o g y . 2 0 1 6 ; 3 4 ( 1 1 ) : 1 2 4 8 – 1 2 5 5 . doi:10.1200/JCO.2015.63.6738
Brinkman TM, Bass JK, Li Z, et al. Treatment-induced hearing loss and adult social outcomes in survivors of childhood CNS and non-CNS solid tumors: Results from the St. Jude Lifetime Cohort S tudy. Canc er. 2 0 1 5 ; 1 2 1 ( 2 2 ) : 4 0 5 3 – 4 0 6 1 . doi:10.1002/cncr.29604
Chole RA, Brodie HA JA. Surgery of the Mastoid and Petrosa. In: Willimns. LW&, ed. Johnson Head and Neck Surgery Otolaryngology. 5th ed. ; 2014:2447.
Romano A, Capozza MA, Mastrangelo S, et al. Assessment and management of platinum–related ototoxicity in children treated for cancer. Cancers (Basel). 2020;12(5):1–15. doi:10.3390/cancers12051266
Paken J, Govender CD, Pillay M, Sewram V. A Review of Cisplatin-Associated Ototoxicity. Seminars in Hearing. 2019;40(2):108–121. doi:10.1055/s-0039-1684041
Wibowo JK, Zizlavsky S, Suwento R, Sjakti HA, Prihartono J. The incidence of ototoxicity in child malignancy cases that received carboplatin therapy with otoacoustic emission (OAE) examination. Journal of Physics: Conference Series. 2017;884(1). doi:10.1088/1742–6596/884/1/012126
Yancey A, Harris MS, Egbelakin A, Gilbert J, Pisoni DB, Renbarger J. Risk factors for cisplatin-associated ototoxicity in pediatric oncology patients. Pediatric Blood & Cancer. 2012;59(1):144–148. doi:10.1002/pbc.24138
Brock P, Rajput K, Edwards L, et al. Cisplatin Ototoxicity in Children. In: Hearing Loss – From Multidisciplinary Teamwork to Public Health [ Working Title] . Intech Open; 2021 . doi:10.5772/intechopen.96744
Peleva E, Emami N, Alzahrani M, et al. Incidence of platinum- induced ototoxicity in pediatric patients in Quebec. Pediatric Blood and Cancer. 2014;61(11):2012–2017. doi:10.1002/pbc.25123
K..J. L. Infections of the Temporal Bone in Essential Otolaryngology. 10th ed.
Gersten BK, Fitzgerald TS, Fernandez KA, Cunningham LL. Ototoxicity and Platinum Uptake Following Cyclic Administration of Platinum–Based Chemotherapeutic Agents. JARO – Journal of the Association for Research in Otolaryngology. 2020;21(4):303–321. doi:10.1007/s10162-020-00759-y
Paken J, Govender CD, Pillay M, Sewram V. Cisplatin- Associated Ototoxicity: A Review for the Health Professional. Journal of Toxicology. 2016;2016. doi:10.1155/2016/1809394
Additional Files
Published
How to Cite
Issue
Section
Citation Check
License
Copyright (c) 2022 muyassaroh - muyassaroh
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
Copyrights Notice
Copyrights:
Researchers publishing manuscrips at Medica Hospitalis: Journal of Clinical Medicine agree with regulations as follow:
Copyrights of each article belong to researchers, and it is likewise the patent rights
Researchers admit that Medica Hospitalia: Journal of Clinical Medicine has the right of first publication
Researchers may submit manuscripts separately, manage non exclusive distribution of published manuscripts into other versions (such as: being sent to researchers’ institutional repository, publication in the books, etc), admitting that manuscripts have been firstly published at Medica Hospitalia: Journal of Clinical Medicine
License:
Medica Hospitalia: Journal of Clinical Medicine is disseminated based on provisions of Creative Common Attribution-Share Alike 4.0 Internasional It allows individuals to duplicate and disseminate manuscripts in any formats, to alter, compose and make derivatives of manuscripts for any purpose. You are not allowed to use manuscripts for commercial purposes. You should properly acknowledge, reference links, and state that alterations have been made. You can do so in proper ways, but it does not hint that the licensors support you or your usage.
